CVS · XBRL financial data

CVS HEALTH financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CVS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	268,706	292,111	322,467	357,776	372,809	402,067
Cost of goods and services sold	163,981	175,803	196,892	217,098	206,287	221,167
Operating income (loss)	13,911	13,193	7,746	13,743	8,516	4,660
Interest expense	2,907	2,503	2,287	2,658	2,958	3,119
Other income (expense)	206	182	169	88	99	112
Income tax expense (benefit)	2,569	2,522	1,463	2,805	1,562	408
Net income (loss)	7,179	7,910	4,149	8,344	4,614	1,768
Earnings per share, basic USD per share	5.48	6.00	3.16	6.49	3.67	1.40
Earnings per share, diluted USD per share	5.46	5.95	3.14	6.47	3.66	1.39
Weighted average shares, basic millions of shares	1,309	1,319	1,312	1,285	1,259	1,267
Weighted average shares, diluted millions of shares	1,314	1,329	1,323	1,290	1,262	1,271

Fiscal years (CVS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	7,854	9,408	12,945	8,196	8,586	8,453
Short-term investments	3,000	3,117	2,778	3,259	2,407	2,145
Accounts receivable	21,742	24,431	27,276	35,227	36,469	39,779
Inventory	18,496	17,760	19,090	18,025	18,107	19,246
Total current assets	56,369	60,008	65,682	67,858	68,645	74,714
Property and equipment, net	12,606	12,896	12,873	—	—	—
Right-of-use asset	20,729	19,122	17,872	17,252	15,944	14,973
Goodwill	79,552	79,121	78,150	91,272	91,272	85,478
Total assets	230,715	232,999	228,275	249,728	253,215	253,538
Accrued liabilities	14,243	17,670	18,745	22,189	20,810	22,387
Commercial paper	—	—	0	200	2,119	0
Total current liabilities	62,017	67,807	69,736	79,189	84,609	88,692
Lease liability, non-current	18,757	18,177	16,800	16,034	14,899	13,643
Total liabilities	161,014	157,618	156,960	173,092	177,485	178,156
Retained earnings	49,640	54,906	56,145	61,604	62,837	61,196
Total stockholders' equity	69,389	75,075	71,015	76,461	75,560	75,214
Total liabilities and equity	230,715	232,999	228,275	249,728	253,215	253,538
Common shares outstanding (cover page) millions of shares	1,311	1,313	1,284	1,258	1,261	1,272

Fiscal years (CVS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	7,179	7,910	4,149	8,344	4,614	1,768
Stock-based compensation	400	484	447	588	540	535
Depreciation and amortization	4,441	4,512	4,247	4,366	4,597	4,606
Net cash from operating activities	15,865	18,265	16,177	13,426	9,107	10,639
Purchases of property and equipment	2,437	2,520	2,727	3,031	2,781	2,832
Net cash from investing activities	(5,534)	(5,261)	(5,047)	(20,889)	(7,613)	(5,871)
Share repurchases	0	0	3,500	2,012	3,023	0
Dividends paid	2,624	2,625	2,907	3,132	3,373	3,397
Proceeds from long-term debt	9,958	987	0	10,898	7,913	3,969
Repayments of long-term debt	15,631	10,254	4,211	3,166	4,773	3,629
Net cash from financing activities	(8,155)	(11,356)	(10,516)	2,683	(1,135)	(4,940)
Net change in cash	2,176	1,648	614	(4,780)	359	(172)

SIC 5912 and related industry codes, similar size; rows marked “added: same SIC” fill a short list. Each row is the latest quarter reported.

How peers are chosen

SIC 5912 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Fewer than three companies fall in that range, so the list adds same-SIC (5912) companies nearest in public float, each marked “added: same SIC”.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
CVS Health	11,738	108,399	4,724*	1.3B	—	Q3 FY26 10-QSep 30, 2026
Guardian Pharmacy Servicesadded: same SIC	90	352	30*	not reported	—	Q2 FY26 10-QJun 30, 2026
Petmed Expressadded: same SIC	13	41	(7.7)	21.7M	1.7 quarters	Q1 FY27 10-QJun 30, 2026
AiXin Life Internationaladded: same SIC	0	0.1*	(0.3)*	25.0M	0.1 quarters	Q4 FY25 10-KDec 31, 2025
TREES Corp (Colorado)added: same SIC	0.2	3.3	0.1*	108.7M	—	Q3 FY24 10-QSep 30, 2024
Flowerkist Skin Care & Cosmeticsadded: same SIC	not reported	not reported	not reported	not reported	—	—
Ridgetechadded: same SIC	18	year only	year only	133.1M	—	Q4 FY26 20-FMar 31, 2026
111added: same SIC	511	year only	year only	not reported	—	Q4 FY25 20-FDec 31, 2025

Not investment advice. Not affiliated with the U.S. SEC.